Trial Profile
A Phase II Randomized, Double-blind, Placebo-controlled Trial of Radium-223 Dichloride in Combination With Exemestane and Everolimus Versus Placebo in Combination With Exemestane and Everolimus When Administered to Metastatic HER2 Negative Hormone Receptor Positive Breast Cancer Subjects With Bone Metastases
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 05 Apr 2024
Price :
$35
*
At a glance
- Drugs Radium 223 chloride (Primary) ; Everolimus; Exemestane
- Indications Adenocarcinoma; Advanced breast cancer; Bone metastases; HER2 negative breast cancer
- Focus Therapeutic Use
- Sponsors Bayer; Bayer HealthCare
- 01 Apr 2024 Results published in the Breast Cancer Research and Treatment
- 04 Nov 2022 Status changed from active, no longer recruiting to completed.
- 31 Aug 2022 Planned End Date changed from 30 Sep 2022 to 30 Oct 2022.